What drugs are contained in Vabomere?

Vabomere (meropenem and vaborbactam) contains meropenem, a carbapenem antibacterial agent, and vaborbactam, a beta-lactamase inhibitor which works to inhibit certain types of resistance mechanisms used by bacteria.

Vabomere is indicated for the treatment of patients 18 years and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex.

Meropenem was first approved under the brand name Merrem for the treatment of skin and skin structure infections, complicated intra-abdominal infections, and bacterial meningitis. Meropenem is a carbapenem antibacterial drug which has a bactericidal action resulting from the inhibition of cell wall synthesis.

Vaborbactam is a beta-lactamase inhibitor that protects meropenem from degradation by certain beta-lactamases. Beta-lactamases are enzymes produced by bacteria that provide resistance to certain antibacterial agents, including carbapenems. Vaborbactam was developed due to the emergence of carbapenem-resistant strains of bacteria.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Vabomere and other antibacterial drugs, Vabomere should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.